Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma

NCT03035331 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03035331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03035331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
August 15, 2017
Completion date
September 10, 2022
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive non-hodgkin lymphoma, indolent non-hodgkin lymphoma, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent non-hodgkin lymphoma, recurrent primary mediastinal (thymic) large b-cell lymphoma, recurrent t-cell non-hodgkin lymphoma, small lymphocytic lymphoma